Lanreotide Autogel® for persistent diabetic macular edema

Diabetes Research and Clinical Practice - Tập 80 - Trang e8-e10 - 2008
Maria C. Hernaez-Ortega1,2, Enrique Soto-Pedre1, José A. Piniés3
1European Innovative Biomedicine Institute (EIBI), Cantabria, Spain
2Department of Ophthalmology, Hospital of Cruces, Vizcaya, Spain
3Department of Endocrinology, Hospital of Cruces, Vizcaya, Spain

Tài liệu tham khảo

Hernaez-Ortega, 2004, Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience, Diabetes Res. Clin. Pract., 64, 71, 10.1016/j.diabres.2003.10.003 Ciulla, 2003, Diabetic retinopathy and diabetic macular edema: pathophhysiology, screening, and novel therapies, Diabetes Care, 26, 2653, 10.2337/diacare.26.9.2653 Simó, 2007, Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema, Diabetes Care, 30, 725, 10.2337/dc06-1345 Kafkala, 2006, Octreotide as a treatment for uveitic cystoid macular edema, Arch. Ophthalmol., 124, 1353, 10.1001/archopht.124.9.1353